Table IV.
Characteristics and oncologic outcomes of patients with recurrence.
| No. | Agea | TNM | Ageb | PFS (months) | Previous treatments | OS (months) | Outcome |
|---|---|---|---|---|---|---|---|
| 1 | 34 | cT1b2N1M0 | 34 | 3 | CCRT (PFx4 kur + WP 56.4 Gy, RALS 15 Gy) | 20 | DOD |
| 2 | 35 | pTisN0M0 | 38 | 16 | VTH → CCRT (PF ×5 kur + WP 50.4 Gy, RALS 13 Gy) | 47 | NED |
| 3 | 37 | cT2bN0M0 | 40 | 4 | CCRT (PFx5 kur + WP 50.4 Gy, RALS 16 Gy) → TC ×6 kur → CPT-11 ×3 kur | 44 | NED |
| 4 | 42 | cT1b2N0M0 | 43 | 7 | CCRT (PFx2 kur + WP 50.4 Gy, RALS 24 Gy) | 13 | DOD |
| 5 | 44 | cT2bN1M0 | 45 | 16 | CCRT (PFx1 kur, CBDCA ×1 kur, NDP ×3 kur + WP 50.4 Gy, RALS 18 Gy) | 41 | NED |
| 6 | 53 | cT1bN0M0 | 54 | 5 | RT (WP 50.4 Gy, RALS 24 Gy) → PF ×2 kur → TP ×4 kur | 24 | DOD |
| 7 | 73 | cT2bN0M0 | 74 | 5 | RT (WP 50.4 Gy, RALS 13 Gy) | 35 | DOD |
| 8 | 73 | cT2aN0M0 | 74 | 10 | RT (WP 50.4 Gy, RALS 9 Gy) | 14 | NED |
a
At diagnosis of uterine cervical cancer
b
At recurrent diagnosis. PFS, progression free survival; OS, overall survival; VTH, vaginal total hysterectomy; CCRT, concurrent chemoradiotherapy; RT, radiotherapy; WP, whole pelvis; RALS, remote after loading system; PF, cisplatin and 5-FU; TC, paclitaxel and carboplatin; CPT-11, irinotecan; CBDCA, carboplatin; NDP, nedaplatin; TP, paclitaxel and cisplatin; DOD, died of disease; NED, no evidence of disease.